Catalyst

Slingshot members are tracking this event:

Merrimack Pharmaceuticals (MACK) initiates Phase 1 study of MM-310 in solid tumors, looking to extract appropriate dosage for Phase 2

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
MACK Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 31, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Mm-310, Solid Tumors, Phase 1